vs
BXP, Inc.（BXP）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
登士柏西诺德的季度营收约是BXP, Inc.的1.1倍（$961.0M vs $872.1M），BXP, Inc.净利率更高（15.3% vs -15.2%，领先30.4%），登士柏西诺德同比增速更快（6.2% vs 0.8%），过去两年BXP, Inc.的营收复合增速更高（1.3% vs 0.4%）
BXP是美国头部商业地产投资信托企业，核心业务为持有、运营及开发A级高端写字楼资产，项目覆盖纽约、波士顿、旧金山等美国核心都市圈，服务企业、科技、专业服务等领域的多元租户。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
BXP vs XRAY — 直观对比
营收规模更大
XRAY
是对方的1.1倍
$872.1M
营收增速更快
XRAY
高出5.4%
0.8%
净利率更高
BXP
高出30.4%
-15.2%
两年增速更快
BXP
近两年复合增速
0.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $872.1M | $961.0M |
| 净利润 | $133.0M | $-146.0M |
| 毛利率 | — | 46.1% |
| 营业利润率 | — | -14.5% |
| 净利率 | 15.3% | -15.2% |
| 营收同比 | 0.8% | 6.2% |
| 净利润同比 | 53.0% | 66.0% |
| 每股收益（稀释后） | $1.69 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BXPXRAY
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $961.0M | ||
| Q3 25 | $871.5M | $904.0M | ||
| Q2 25 | $868.5M | $936.0M | ||
| Q1 25 | $865.2M | $879.0M | ||
| Q4 24 | $858.6M | $905.0M | ||
| Q3 24 | $859.2M | $951.0M | ||
| Q2 24 | $850.5M | $984.0M |
净利润BXPXRAY
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $-146.0M | ||
| Q3 25 | $-121.7M | $-427.0M | ||
| Q2 25 | $89.0M | $-45.0M | ||
| Q1 25 | $61.2M | $20.0M | ||
| Q4 24 | $-228.9M | $-430.0M | ||
| Q3 24 | $83.6M | $-494.0M | ||
| Q2 24 | $79.6M | $-4.0M |
毛利率BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | 46.1% | ||
| Q3 25 | 59.3% | 48.8% | ||
| Q2 25 | 59.2% | 52.4% | ||
| Q1 25 | 59.2% | 53.0% | ||
| Q4 24 | 59.7% | 49.3% | ||
| Q3 24 | 59.5% | 52.1% | ||
| Q2 24 | 59.8% | 51.9% |
营业利润率BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | — | -14.5% | ||
| Q3 25 | — | -24.1% | ||
| Q2 25 | — | -13.7% | ||
| Q1 25 | — | 7.2% | ||
| Q4 24 | — | -56.2% | ||
| Q3 24 | — | -48.6% | ||
| Q2 24 | — | 5.1% |
净利率BXPXRAY
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | -15.2% | ||
| Q3 25 | -14.0% | -47.2% | ||
| Q2 25 | 10.2% | -4.8% | ||
| Q1 25 | 7.1% | 2.3% | ||
| Q4 24 | -26.7% | -47.5% | ||
| Q3 24 | 9.7% | -51.9% | ||
| Q2 24 | 9.4% | -0.4% |
每股收益（稀释后）BXPXRAY
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $-0.74 | ||
| Q3 25 | $-0.77 | $-2.14 | ||
| Q2 25 | $0.56 | $-0.22 | ||
| Q1 25 | $0.39 | $0.10 | ||
| Q4 24 | $-1.46 | $-2.09 | ||
| Q3 24 | $0.53 | $-2.46 | ||
| Q2 24 | $0.51 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $512.8M | $326.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $7.7B | $1.3B |
| 总资产 | $25.1B | $5.4B |
| 负债/权益比越低杠杆越低 | — | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资BXPXRAY
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | $326.0M | ||
| Q3 25 | $861.1M | $363.0M | ||
| Q2 25 | $447.0M | $359.0M | ||
| Q1 25 | $398.1M | $398.0M | ||
| Q4 24 | $1.3B | $272.0M | ||
| Q3 24 | $1.4B | $296.0M | ||
| Q2 24 | $685.4M | $279.0M |
总债务BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益BXPXRAY
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $1.3B | ||
| Q3 25 | $5.0B | $1.5B | ||
| Q2 25 | $5.3B | $2.0B | ||
| Q1 25 | $5.3B | $2.0B | ||
| Q4 24 | $5.4B | $1.9B | ||
| Q3 24 | $5.8B | $2.5B | ||
| Q2 24 | $5.8B | $3.1B |
总资产BXPXRAY
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $5.4B | ||
| Q3 25 | $26.0B | $5.7B | ||
| Q2 25 | $25.6B | $6.1B | ||
| Q1 25 | $25.4B | $6.0B | ||
| Q4 24 | $26.1B | $5.8B | ||
| Q3 24 | $26.4B | $6.6B | ||
| Q2 24 | $25.5B | $6.9B |
负债/权益比BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $101.0M |
| 自由现金流经营现金流 - 资本支出 | — | $60.0M |
| 自由现金流率自由现金流/营收 | — | 6.2% |
| 资本支出强度资本支出/营收 | 1.5% | 4.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $104.0M |
8季度趋势，按日历期对齐
经营现金流BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $101.0M | ||
| Q3 25 | $274.2M | $79.0M | ||
| Q2 25 | $353.1M | $48.0M | ||
| Q1 25 | $210.0M | $7.0M | ||
| Q4 24 | $383.7M | $87.0M | ||
| Q3 24 | $286.1M | $141.0M | ||
| Q2 24 | $367.1M | $208.0M |
自由现金流BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $60.0M | ||
| Q3 25 | $231.6M | $40.0M | ||
| Q2 25 | $281.5M | $16.0M | ||
| Q1 25 | $152.6M | $-12.0M | ||
| Q4 24 | $312.5M | $36.0M | ||
| Q3 24 | $234.5M | $98.0M | ||
| Q2 24 | $332.4M | $156.0M |
自由现金流率BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 6.2% | ||
| Q3 25 | 26.6% | 4.4% | ||
| Q2 25 | 32.4% | 1.7% | ||
| Q1 25 | 17.6% | -1.4% | ||
| Q4 24 | 36.4% | 4.0% | ||
| Q3 24 | 27.3% | 10.3% | ||
| Q2 24 | 39.1% | 15.9% |
资本支出强度BXPXRAY
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 4.3% | ||
| Q3 25 | 4.9% | 4.3% | ||
| Q2 25 | 8.2% | 3.4% | ||
| Q1 25 | 6.6% | 2.2% | ||
| Q4 24 | 8.3% | 5.6% | ||
| Q3 24 | 6.0% | 4.5% | ||
| Q2 24 | 4.1% | 5.3% |
现金转化率BXPXRAY
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.97× | — | ||
| Q1 25 | 3.43× | 0.35× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.42× | — | ||
| Q2 24 | 4.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
